Literature DB >> 24140727

Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment--role of brain kynurenic acid.

Xi-Cong Liu1, Maria Holtze1, Susan B Powell2, Niccolò Terrando1, Markus K Larsson1, Anna Persson1, Sara K Olsson1, Funda Orhan1, Magdalena Kegel1, Linnea Asp3, Michel Goiny1, Lilly Schwieler1, Göran Engberg1, Håkan Karlsson3, Sophie Erhardt4.   

Abstract

Exposure to infections in early life is considered a risk-factor for developing schizophrenia. Recently we reported that a neonatal CNS infection with influenza A virus in mice resulted in a transient induction of the brain kynurenine pathway, and subsequent behavioral disturbances in immune-deficient adult mice. The aim of the present study was to investigate a potential role in this regard of kynurenic acid (KYNA), an endogenous antagonist at the glycine site of the N-methyl-D-aspartic acid (NMDA) receptor and at the cholinergic α7 nicotinic receptor. C57BL/6 mice were injected i.p. with neurotropic influenza A/WSN/33 virus (2400 plaque-forming units) at postnatal day (P) 3 or with L-kynurenine (2×200 mg/kg/day) at P7-16. In mice neonatally treated with L-kynurenine prepulse inhibition of the acoustic startle, anxiety, and learning and memory were also assessed. Neonatally infected mice showed enhanced sensitivity to D-amphetamine-induced (5 mg/kg i.p.) increase in locomotor activity as adults. Neonatally L-kynurenine treated mice showed enhanced sensitivity to D-amphetamine-induced (5 mg/kg i.p.) increase in locomotor activity as well as mild impairments in prepulse inhibition and memory. Also, D-amphetamine tended to potentiate dopamine release in the striatum in kynurenine-treated mice. These long-lasting behavioral and neurochemical alterations suggest that the kynurenine pathway can link early-life infection with the development of neuropsychiatric disturbances in adulthood.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphetamine; Immune activation; Kynurenine; Locomotor activity; Microdialysis; Neurodevelopment; Postnatal; Prepulse inhibition; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 24140727      PMCID: PMC3947209          DOI: 10.1016/j.bbi.2013.10.010

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  87 in total

1.  Elevated cerebrospinal fluid kynurenic acid levels in patients with tick-borne encephalitis.

Authors:  M Holtze; A Mickiené; A Atlas; L Lindquist; L Schwieler
Journal:  J Intern Med       Date:  2012-04-19       Impact factor: 8.989

2.  Maternal antibodies to infectious agents and risk for non-affective psychoses in the offspring--a matched case-control study.

Authors:  Asa Blomström; Håkan Karlsson; Susanne Wicks; Shuojia Yang; Robert H Yolken; Christina Dalman
Journal:  Schizophr Res       Date:  2012-07-21       Impact factor: 4.939

3.  Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input.

Authors:  H S Hoffman; J R Ison
Journal:  Psychol Rev       Date:  1980-03       Impact factor: 8.934

4.  The use of a plus-maze to measure anxiety in the mouse.

Authors:  R G Lister
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

Review 6.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

7.  Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder.

Authors:  Sara K Olsson; Carl Sellgren; Göran Engberg; Mikael Landén; Sophie Erhardt
Journal:  Bipolar Disord       Date:  2012-10-03       Impact factor: 6.744

Review 8.  Recent advances in the phencyclidine model of schizophrenia.

Authors:  D C Javitt; S R Zukin
Journal:  Am J Psychiatry       Date:  1991-10       Impact factor: 18.112

9.  Behavioral effects of neonatal herpes simplex type 1 infection of mice.

Authors:  L S Crnic; L I Pizer
Journal:  Neurotoxicol Teratol       Date:  1988 Jul-Aug       Impact factor: 3.763

10.  Exploration of mice in a black and white test box: validation as a model of anxiety.

Authors:  B Costall; B J Jones; M E Kelly; R J Naylor; D M Tomkins
Journal:  Pharmacol Biochem Behav       Date:  1989-03       Impact factor: 3.533

View more
  18 in total

Review 1.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 2.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

3.  Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.

Authors:  Sarah Beggiato; Alessandro Ieraci; Maria Cristina Tomasini; Robert Schwarcz; Luca Ferraro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-02-04       Impact factor: 5.067

4.  Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.

Authors:  Lilly Schwieler; Markus K Larsson; Elisabeth Skogh; Magdalena E Kegel; Funda Orhan; Sally Abdelmoaty; Anja Finn; Maria Bhat; Martin Samuelsson; Kristina Lundberg; Marja-Liisa Dahl; Carl Sellgren; Ina Schuppe-Koistinen; Camilla Svensson; Sophie Erhardt; Göran Engberg
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

Review 5.  Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer.

Authors:  Masaru Tanaka; Eleonóra Spekker; Ágnes Szabó; Helga Polyák; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2022-05-28       Impact factor: 3.850

6.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

Review 7.  Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Authors:  Francesca M Notarangelo; Ana Pocivavsek
Journal:  Neuropharmacology       Date:  2016-03-02       Impact factor: 5.250

Review 8.  Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.

Authors:  R Schwarcz
Journal:  Adv Pharmacol       Date:  2016-03-11

9.  Inflammatory and oxidative stress-related effects associated with neurotoxicity are maintained after exclusively prenatal trichloroethylene exposure.

Authors:  Sarah J Blossom; Stepan B Melnyk; Ming Li; William D Wessinger; Craig A Cooney
Journal:  Neurotoxicology       Date:  2016-01-23       Impact factor: 4.294

Review 10.  Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Authors:  Jennifer M Parrott; Jason C O'Connor
Journal:  Front Psychiatry       Date:  2015-08-20       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.